Radionuclide therapy using 131I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression

详细信息    查看全文

• 作者：Wei Li ; Zhongyun Liu ; Chengxia Li ; Ning Li…
• 关键词：Epidermal growth factor receptor ; Nanoparticles ; 131I ; Radioiodine therapy ; Tumor ; targeting
• 刊名：Journal of Cancer Research and Clinical Oncology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：142
• 期：3
• 页码：619-632
• 全文大小：1,833 KB
• 参考文献：Almutairi A, Rossin R, Shokeen M, Hagooly A, Ananth A, Capoccia B, Guillaudeu S, Abendschein D, Anderson CJ, Welch MJ, Frechet JM (2009) Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci USA 106:685–690PubMedCentral CrossRef PubMed
  Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350–7356PubMed
  Bandekar A, Zhu C, Jindal R, Bruchertseifer F, Morgenstern A, Sofou S (2014) Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular alpha-particle therapy of cancer. J Nucl Med 55:107–114CrossRef PubMed
  Brand TM, Iida M, Li C, Wheeler DL (2011) The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 12:419–432PubMedCentral PubMed
  Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart MJ (2013) Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol 24:273–282CrossRef PubMed
  Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T, Tennvall J (2003) Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 66:107–117CrossRef PubMed
  Chen K, Li ZB, Wang H, Cai W, Chen X (2008) Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging 35:2235–2244CrossRef PubMed
  Chen S, Zhao X, Chen J, Kuznetsova L, Wong SS, Ojima I (2010) Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug Chem 21:979–987PubMedCentral CrossRef PubMed
  Chen CL, Hu GY, Mei Q, Qiu H, Long GX, Hu GQ (2012) Epidermal growth factor receptor-targeted ultra-small superparamagnetic iron oxide particles for magnetic resonance molecular imaging of lung cancer cells in vitro. Chin Med J (Engl) 125:2322–2328
  Chen Y, Peng J, Han M, Omar M, Hu D, Ke X, Lu N (2015) A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of melanoma metastasis. J Drug Target 23:335–346CrossRef PubMed
  Cho YS, Yoon TJ, Jang ES, Soo Hong K, Young Lee S, Ran Kim O, Park C, Kim YJ, Yi GC, Chang K (2010) Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging. Cancer Lett 299:63–71CrossRef PubMed
  Chung TH, Hsiao JK, Hsu SC, Yao M, Chen YC, Wang SW, Kuo MY, Yang CS, Huang DM (2011) Iron oxide nanoparticle-induced epidermal growth factor receptor expression in human stem cells for tumor therapy. ACS Nano 5:9807–9816CrossRef PubMed
  Du C, Deng D, Shan L, Wan S, Cao J, Tian J, Achilefu S, Gu Y (2013) A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery. Biomaterials 34:3087–3097CrossRef PubMed
  Elbayoumi TA, Pabba S, Roby A, Torchilin VP (2007) Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res 17:1–14CrossRef PubMed
  Fondell A, Edwards K, Unga J, Kullberg E, Park JW, Gedda L (2011) In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an (125)I-labelled DNA-intercalator. J Drug Target 19:846–855CrossRef PubMed
  Giaccone G (2005) HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol 16:538–548CrossRef PubMed
  Gupta B, Torchilin VP (2007) Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol Immunother 56:1215–1223CrossRef PubMed
  Hu G, Lijowski M, Zhang H, Partlow KC, Caruthers SD, Kiefer G, Gulyas G, Athey P, Scott MJ, Wickline SA, Lanza GM (2007) Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted 111In nanoparticles. Int J Cancer 120:1951–1957CrossRef PubMed
  Hussain AF, Kruger HR, Kampmeier F, Weissbach T, Licha K, Kratz F, Haag R, Calderon M, Barth S (2013) Targeted delivery of dendritic polyglycerol–doxorubicin conjugates by scFv-SNAP fusion protein suppresses EGFR+ cancer cell growth. Biomacromolecules 14:2510–2520CrossRef PubMed
  Jung KH, Choe YS, Paik JY, Lee KH (2011) 99mTc-Hydrazinonicotinamide epidermal growth factor-polyethylene glycol-quantum dot imaging allows quantification of breast cancer epidermal growth factor receptor expression and monitors receptor downregulation in response to cetuximab therapy. J Nucl Med 52:1457–1464CrossRef PubMed
  Kao HW, Lin YY, Chen CC, Chi KH, Tien DC, Hsia CC, Lin MH, Wang HE (2013) Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model. Bioorg Med Chem Lett 23:3180–3185CrossRef PubMed
  Kim YH, Jeon J, Hong SH, Rhim WK, Lee YS, Youn H, Chung JK, Lee MC, Lee DS, Kang KW, Nam JM (2011) Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125. Small 7:2052–2060CrossRef PubMed
  Lee HY, Li Z, Chen K, Hsu AR, Xu C, Xie J, Sun S, Chen X (2008) PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 49:1371–1379CrossRef PubMed
  Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S, Lee DY, Bednarski MD, Knox SJ (2004) A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys 58:1215–1227CrossRef PubMed
  Liu Z, Dong C, Wang X, Wang H, Li W, Tan J, Chang J (2014) Self-assembled biodegradable protein-polymer vesicle as a tumor-targeted nanocarrier. ACS Appl Mater Interfaces 6:2393–2400CrossRef PubMed
  Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW (2003) Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 63:3154–3161PubMed
  Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW (2005) Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65:11631–11638CrossRef PubMed
  Mamot C, Ritschard R, Kung W, Park JW, Herrmann R, Rochlitz CF (2006) EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J Drug Target 14:215–223CrossRef PubMed
  McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, Brentjens R, Scheinberg DA (2007) Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 48:1180–1189CrossRef PubMed
  Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3:488–499CrossRef PubMed
  Mitra A, Nan A, Line BR, Ghandehari H (2006) Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des 12:4729–4749CrossRef PubMed
  Nagaria TS, Williams JL, Leduc C, Squire JA, Greer PA, Sangrar W (2013) Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems. Neoplasia 15:939–951PubMedCentral CrossRef PubMed
  Neff CP, Zhou J, Remling L, Kuruvilla J, Zhang J, Li H, Smith DD, Swiderski P, Rossi JJ, Akkina R (2011) An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 3:66ra66CrossRef
  Nordberg E, Friedman M, Gostring L, Adams GP, Brismar H, Nilsson FY, Stahl S, Glimelius B, Carlsson J (2007) Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol 34:609–618CrossRef PubMed
  Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F (2009) Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 6:519–527CrossRef PubMed
  Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, Ponzoni M (2003) Doxorubicin-loaded Fab’ fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 63:86–92PubMed
  Pinhassi RI, Assaraf YG, Farber S, Stark M, Ickowicz D, Drori S, Domb AJ, Livney YD (2010) Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules 11:294–303CrossRef PubMed
  Saha RN, Vasanthakumar S, Bende G, Snehalatha M (2010) Nanoparticulate drug delivery systems for cancer chemotherapy. Mol Membr Biol 27:215–231CrossRef PubMed
  Su W, Wang H, Wang S, Liao Z, Kang S, Peng Y, Han L, Chang J (2012) PEG/RGD-modified magnetic polymeric liposomes for controlled drug release and tumor cell targeting. Int J Pharm 426:170–181CrossRef PubMed
  Ting G, Chang CH, Wang HE, Lee TW (2010) Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy. J Biomed Biotechnol 2010:1–17. doi:10.​1155/​2010/​953537 CrossRef
  Yang FY, Wang HE, Liu RS, Teng MC, Li JJ, Lu M, Wei MC, Wong TT (2012) Pharmacokinetic analysis of 111 in-labeled liposomal Doxorubicin in murine glioblastoma after blood
  ain barrier disruption by focused ultrasound. PLoS ONE 7:e45468PubMedCentral CrossRef PubMed
  Zhou X, Qiu J, Wang Z, Huang N, Li X, Li Q, Zhang Y, Zhao C, Luo C, Zhang N, Teng X, Chen Z, Liu X, Yu X, Wu W, Wei YQ, Li J (2012) In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin. J Cancer Res Clin Oncol 138:1081–1090CrossRef PubMed
  
• 作者单位：Wei Li (1)
  Zhongyun Liu (2)
  Chengxia Li (1)
  Ning Li (1)
  Lei Fang (3)
  Jin Chang (3)
  Jian Tan (1)
  
  1. Department of Nuclear Medicine, Tianjin Medical University General Hospital, Anshan Road 154, Heping District, Tianjin, 300052, People’s Republic of China
  2. Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, Shandong, People’s Republic of China
  3. Institute of Nanobiotechnology, School of Materials Science and Engineering, Tianjin Key Laboratory of Composites and Functional Materials, Tianjin University, Tianjin, 300072, People’s Republic of China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Cancer Research
  Internal Medicine
  Hematology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1335

文摘

Introduction Anti-epidermal growth factor receptor (EGFR)-targeted nanoparticles can be used to deliver a therapeutic and imaging agent to EGFR-overexpressing tumor cells. 131I-labeled anti-EGFR nanoparticles derived from cetuximab were used as a tumor-targeting vehicle in radionuclide therapy.